ERBB2 and breast cancer: Several ongoing studies are investigating the efficacy and safety of A166 in different HER2-expressing solid tumour types, including HER2-low breast cancer (CTR20181301), NSCLC (CTR20210516), and urothelial carcinoma (CTR20211319).